B7-H3-targeted Radioimmunotherapy of Human Cancer.
B7-H3
Radioimmunoconjugates (RICs)
Targeted radioimmunotherapy
cancer
mAb
radiotherapy
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2018
revised:
28
01
2019
accepted:
28
01
2019
pubmed:
7
3
2019
medline:
1
9
2020
entrez:
7
3
2019
Statut:
ppublish
Résumé
Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human malignancies express B7-H3 on the tumor cell surface, while expression on the majority of normal tissues is limited, presenting B7-H3 as a candidate target for RIT. This review provides an overview of the general principles of targeted RIT and discusses publications that have used radiolabeled B7-H3-targeted antibodies for RIT of cancer in preclinical or clinical studies. Databases including PubMed, Scopus, and Google Scholar were searched for publications through June 2018 using a combination of terms including "B7-H3", "radioimmunotherapy", "targeted", "radiotherapy", and "cancer". After screening search results for relevancy, ten publications were included for discussion. B7-H3-targeted RIT studies to date range from antibody development and assessment of novel Radioimmunoconjugates (RICs) in animal models of human cancer to phase II/III trials in humans. The majority of clinical studies have used B7-H3-targeted RICs for intra- compartment RIT of central nervous system malignancies. The results of these studies have indicated high tolerability and favorable efficacy outcomes, supporting further assessment of B7-H3-targeted RIT in larger trials. Preclinical B7-H3-targeted RIT studies have also shown encouraging therapeutic outcomes in a variety of solid malignancies. B7-H3-targeted RIT studies over the last 15 years have demonstrated feasibility for clinical development and support future assessment in a broader array of human malignancies. Future directions worthy of exploration include strategies that combine B7-H3- targeted RIT with chemotherapy or immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human malignancies express B7-H3 on the tumor cell surface, while expression on the majority of normal tissues is limited, presenting B7-H3 as a candidate target for RIT. This review provides an overview of the general principles of targeted RIT and discusses publications that have used radiolabeled B7-H3-targeted antibodies for RIT of cancer in preclinical or clinical studies.
METHODS
METHODS
Databases including PubMed, Scopus, and Google Scholar were searched for publications through June 2018 using a combination of terms including "B7-H3", "radioimmunotherapy", "targeted", "radiotherapy", and "cancer". After screening search results for relevancy, ten publications were included for discussion.
RESULTS
RESULTS
B7-H3-targeted RIT studies to date range from antibody development and assessment of novel Radioimmunoconjugates (RICs) in animal models of human cancer to phase II/III trials in humans. The majority of clinical studies have used B7-H3-targeted RICs for intra- compartment RIT of central nervous system malignancies. The results of these studies have indicated high tolerability and favorable efficacy outcomes, supporting further assessment of B7-H3-targeted RIT in larger trials. Preclinical B7-H3-targeted RIT studies have also shown encouraging therapeutic outcomes in a variety of solid malignancies.
CONCLUSION
CONCLUSIONS
B7-H3-targeted RIT studies over the last 15 years have demonstrated feasibility for clinical development and support future assessment in a broader array of human malignancies. Future directions worthy of exploration include strategies that combine B7-H3- targeted RIT with chemotherapy or immunotherapy.
Identifiants
pubmed: 30836909
pii: CMC-EPUB-96941
doi: 10.2174/0929867326666190228120908
pmc: PMC8668195
mid: NIHMS1761224
doi:
Substances chimiques
Antibodies, Monoclonal
0
B7 Antigens
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4016-4038Subventions
Organisme : NCI NIH HHS
ID : R03 CA231766
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA223886
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028172
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA216114
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA239193
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA173120
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS048039
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013148
Pays : United States
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):173-8
pubmed: 26522223
Curr Neuropharmacol. 2017;15(1):116-128
pubmed: 27306036
Mod Pathol. 2010 Aug;23(8):1104-12
pubmed: 20495537
J Med Chem. 2009 Jul 9;52(13):3829-45
pubmed: 19309080
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
Cancer Res. 2012 Feb 15;72(4):897-907
pubmed: 22186138
Curr Radiopharm. 2013 Jun 6;6(2):78-86
pubmed: 23551110
Tumour Biol. 2012 Jun;33(3):573-90
pubmed: 22143940
Curr Drug Deliv. 2011 Jan;8(1):26-44
pubmed: 21034423
Mol Cancer Ther. 2012 Jul;11(7):1587-97
pubmed: 22553355
Br J Cancer. 2014 Jul 8;111(1):149-56
pubmed: 24892449
Blood. 2009 May 14;113(20):4903-13
pubmed: 19124831
J Natl Cancer Inst. 1982 May;68(5):761-9
pubmed: 6951087
Phys Med Biol. 1996 Oct;41(10):1973-92
pubmed: 8912375
World J Nucl Med. 2011 Jul;10(2):122-38
pubmed: 22144871
Science. 2001 Nov 16;294(5546):1537-40
pubmed: 11711678
Bioconjug Chem. 2015 Feb 18;26(2):176-92
pubmed: 25494884
Theranostics. 2017 Oct 13;7(18):4551-4565
pubmed: 29158844
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Clin Cancer Res. 1999 Oct;5(10 Suppl):3254s-3258s
pubmed: 10541372
Cancer Res. 1995 Feb 15;55(4):878-84
pubmed: 7850803
Cancer Res. 2007 Mar 1;67(5):2187-96
pubmed: 17332349
Cancer Treat Rev. 2018 Sep;69:152-163
pubmed: 30029203
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
J Clin Oncol. 2005 Jun 10;23(17):3912-22
pubmed: 15851766
Cancer Res. 2009 Dec 1;69(23):8941-8
pubmed: 19920193
J Nucl Med. 2016 Apr;57(4):594-600
pubmed: 26769860
Nature. 2003 Oct 23;425(6960):846-51
pubmed: 14520411
Semin Nucl Med. 2010 Mar;40(2):122-35
pubmed: 20113680
Gynecol Oncol. 2014 Jan;132(1):203-10
pubmed: 24216048
Cancer Res. 1995 Dec 1;55(23 Suppl):5729s-5732s
pubmed: 7493336
Semin Radiat Oncol. 2000 Apr;10(2):156-67
pubmed: 10727604
J Nucl Med. 2016 Oct;57(10):1569-1575
pubmed: 27230930
Lancet Oncol. 2018 Aug;19(8):1040-1050
pubmed: 29914796
NPJ Breast Cancer. 2018 Jan 11;4:1
pubmed: 29354686
J Surg Res. 2012 Mar;173(1):105-12
pubmed: 22099597
Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):569-76
pubmed: 26460999
Semin Nucl Med. 2016 Mar;46(2):165-79
pubmed: 26897720
Surgery. 2007 Apr;141(4):415-9
pubmed: 17383517
Cancers (Basel). 2018 Jul 24;10(8):
pubmed: 30042330
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Breast. 2018 Apr;38:66-74
pubmed: 29253718
J Nucl Med. 1999 Jan;40(1):11S-36S
pubmed: 9935083
Tissue Antigens. 2005 Aug;66(2):83-92
pubmed: 16029427
Cancer. 2003 Jul 1;98(1):155-65
pubmed: 12833468
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10277-8
pubmed: 18650376
Med Oncol. 2014 Dec;31(12):349
pubmed: 25416051
Cancer Res. 2008 May 15;68(10):3873-80
pubmed: 18483272
Am J Clin Oncol. 2018 Jul;41(7):716-721
pubmed: 27906723
Int J Mol Sci. 2018 Mar 21;19(4):
pubmed: 29561763
Annu Rev Med. 2007;58:267-84
pubmed: 17002552
Oncotarget. 2016 Apr 26;7(17):24888-98
pubmed: 27058890
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
Cancer Res. 2016 Oct 15;76(20):5994-6005
pubmed: 27550452
Int J Cancer. 1998 May 29;76(5):738-48
pubmed: 9610734
Target Oncol. 2013 Sep;8(3):159-172
pubmed: 23314952
Front Oncol. 2014 Jan 14;3:324
pubmed: 24459634
Mol Cancer Ther. 2018 Jul;17(7):1355-1364
pubmed: 29967214
Nucl Med Biol. 2018 Mar;58:67-73
pubmed: 29413459
J Neurosurg Pediatr. 2017 Sep;20(3):256-260
pubmed: 28686124
J Korean Neurosurg Soc. 2018 May;61(3):343-351
pubmed: 29742880
Curr Radiopharm. 2018;11(3):192-199
pubmed: 29793418
Cancer Biother Radiopharm. 2002 Aug;17(4):435-43
pubmed: 12396707
Oncotarget. 2015 Sep 15;6(27):23720-34
pubmed: 26125441
Cell Physiol Biochem. 2016;39(4):1568-80
pubmed: 27626927
J Nucl Med. 2009 Jul;50(7):1153-60
pubmed: 19525452
Blood. 2018 Feb 8;131(6):611-620
pubmed: 29158362
AIMS Med Sci. 2015;2(3):228-245
pubmed: 26858987
Trends Cancer. 2018 Jun;4(6):401-404
pubmed: 29860983
J Nucl Med. 2014 Oct;55(10):1636-42
pubmed: 25157044
Clin Cancer Res. 2017 Sep 15;23(18):5514-5526
pubmed: 28533222
Blood. 2017 Jun 22;129(25):3386-3388
pubmed: 28476749
PLoS One. 2012;7(1):e30815
pubmed: 22303460
Expert Opin Biol Ther. 2016 Aug;16(8):1035-47
pubmed: 27145158
Cancer Res. 2009 Aug 1;69(15):6275-81
pubmed: 19584290
Cancer Res. 2001 May 15;61(10):4048-54
pubmed: 11358824
Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1251-61
pubmed: 12830326
Semin Cancer Biol. 2018 Dec;53:90-109
pubmed: 29966677
Clin Cancer Res. 2010 Nov 1;16(21):5303-11
pubmed: 20858843
Nucl Med Biol. 2017 Apr;47:23-30
pubmed: 28104527
J Immunol. 2004 Feb 15;172(4):2352-9
pubmed: 14764704
PLoS One. 2013 Jul 04;8(7):e67811
pubmed: 23861811
J Radiat Res. 2017 Nov 1;58(6):870-880
pubmed: 28992050
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Cancer Gene Ther. 2015 Aug;22(8):375-9
pubmed: 26227823
PLoS One. 2013 Jul 29;8(7):e69613
pubmed: 23922757
J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512
pubmed: 20852124
Crit Rev Oncol Hematol. 2016 Sep;105:5-17
pubmed: 27497027
J Neurooncol. 2015 Jun;123(2):245-9
pubmed: 25944385
Cancers (Basel). 2015 Jul 21;7(3):1333-48
pubmed: 26197339
Tumour Biol. 2015 Jun;36(6):4053-62
pubmed: 25926382
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
J Nucl Med. 2017 Apr;58(4):598-604
pubmed: 27688477
J Biol Chem. 2015 Dec 11;290(50):30018-29
pubmed: 26487718
Nat Rev Cancer. 2013 Jan;13(1):11-26
pubmed: 23258168
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Expert Opin Biol Ther. 2017 Jul;17(7):813-819
pubmed: 28438082
Neuro Oncol. 2014 Jun;16(6):800-6
pubmed: 24526309
Cancer Biother Radiopharm. 2005 Oct;20(5):557-68
pubmed: 16248771
Clin Cancer Res. 2015 May 1;21(9):2157-66
pubmed: 25623215
J Nucl Med. 2014 Sep;55(9):1557-64
pubmed: 25012457
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
J Neurooncol. 2010 May;97(3):409-18
pubmed: 19890606
Pharmacol Ther. 2018 Jul;187:13-30
pubmed: 29421575
Cancer Biol Ther. 2007 May;6(5):795-801
pubmed: 17387270
Gynecol Oncol Rep. 2017 Mar 21;20:81-86
pubmed: 28378010
Oncol Rep. 1998 Jan-Feb;5(1):223-6
pubmed: 9458326
Onco Targets Ther. 2014 Oct 29;7:1979-86
pubmed: 25378933
Int J Mol Sci. 2018 May 20;19(5):
pubmed: 29783777
Nucl Med Mol Imaging. 2016 Jun;50(2):104-11
pubmed: 27275358
Clin Cancer Res. 2008 Aug 15;14(16):5150-7
pubmed: 18694993
Cancer Biol Ther. 2005 Aug;4(8):848-53
pubmed: 16082185
Cancer Biother Radiopharm. 2005 Oct;20(5):534-46
pubmed: 16248769
Clin Exp Metastasis. 2005;22(7):575-86
pubmed: 16475028
Oncol Rep. 2007 Oct;18(4):769-74
pubmed: 17786334
Br J Cancer. 2013 Feb 19;108(3):479-85
pubmed: 23299535
Cancer Res. 2016 Jul 1;76(13):3978-88
pubmed: 27216178
Anticancer Res. 2017 Jun;37(6):2761-2775
pubmed: 28551612
Cancer Immunol Immunother. 2010 Aug;59(8):1163-71
pubmed: 20333377
Trends Cancer. 2016 Nov;2(11):638-645
pubmed: 28741502
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Gynecol Oncol. 1997 Apr;65(1):94-101
pubmed: 9103398
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Neoplasia. 2008 Sep;10(9):1021-7
pubmed: 18714364
Nucl Med Biol. 2009 May;36(4):395-402
pubmed: 19423007
Radiology. 2016 Mar;278(3):897-905
pubmed: 26406550
Lung Cancer. 2009 Nov;66(2):245-9
pubmed: 19269710
Cancer. 2017 Feb 15;123(4):638-649
pubmed: 27763687
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1766-71
pubmed: 24443552
Blood. 2002 Aug 15;100(4):1233-9
pubmed: 12149203
World J Stem Cells. 2014 Sep 26;6(4):441-7
pubmed: 25258665
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348
pubmed: 29534618
Oncogenesis. 2017 Apr 3;6(4):e310
pubmed: 28368389
Cancer Biother Radiopharm. 2004 Dec;19(6):669-72
pubmed: 15665615
Cell Prolif. 2015 Apr;48(2):249-58
pubmed: 25643607
Oncogene. 2015 Apr 30;34(18):2297-308
pubmed: 24954508
Stem Cell Reports. 2017 May 9;8(5):1392-1407
pubmed: 28457887
Immunotherapy. 2011 Sep;3(9):1041-50
pubmed: 21913827
J Nucl Med. 2010 Feb;51(2):311-28
pubmed: 20080889
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450
Am J Clin Exp Immunol. 2017 Jun 15;6(4):66-75
pubmed: 28695059
Cancer Biother Radiopharm. 2008 Feb;23(1):92-107
pubmed: 18298333
EJNMMI Res. 2017 Dec;7(1):57
pubmed: 28721684
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5643s-5645s
pubmed: 17875801
Lancet Oncol. 2014 May;15(6):569-79
pubmed: 24739896
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
Semin Oncol. 2014 Oct;41(5):685-99
pubmed: 25440613
Int J Cancer. 2007 Jun 15;120(12):2710-4
pubmed: 17354223